Intersect ENT (XENT) Tops Q2 EPS by 3c, FY Revenue Guidance Misses

Intersect ENT (NASDAQ: XENT) reported Q2 EPS of ($0.14), $0.03 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $26.3 million versus the consensus estimate of $28.15 million.

Outlook

The company expects to achieve third quarter revenue in the range of $23.8 to $24.3 million, and updated full year revenue guidance to $106 to $109 million, including an estimated 2% to 4% contribution from SINUVA product sales. The company expects third quarter and full year gross margin of approximately 80% and full year operating expenses, as previously guided, in the range of $113 to $115 million.

(Street sees Q2 revenue of $27.57 million and FY revenue of $116.29 million)

For earnings history and earnings-related data on Intersect ENT (XENT) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
• Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c